Stevens-Johnson syndrome
ICD-10 L51.1 is a billable code used to indicate a diagnosis of stevens-johnson syndrome.
Stevens-Johnson syndrome (SJS) is a severe mucocutaneous reaction characterized by extensive necrosis and detachment of the epidermis. It often presents with flu-like symptoms, followed by the development of painful red or purplish skin lesions that can progress to blistering and sloughing of the skin. The condition primarily affects the skin and mucous membranes, including the eyes, mouth, and genitals. The pathophysiology involves a hypersensitivity reaction, most commonly triggered by medications, infections, or other environmental factors. Disease progression can lead to significant complications, including secondary infections, dehydration, and ocular damage, which may result in permanent vision loss. Diagnosis is primarily clinical, supported by patient history and physical examination, with a focus on identifying potential triggers. Early recognition and intervention are crucial to improving outcomes, as SJS can rapidly progress to toxic epidermal necrolysis (TEN), a more severe form of skin detachment. Management typically involves hospitalization, supportive care, and discontinuation of the offending agent, with potential use of systemic corticosteroids or immunoglobulins in severe cases.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
L51.1 specifically covers Stevens-Johnson syndrome, which is characterized by the detachment of the epidermis and mucosal involvement. It is essential to differentiate it from other conditions like erythema multiforme and toxic epidermal necrolysis, which have different clinical implications and management strategies.
L51.1 should be used when a patient presents with symptoms consistent with Stevens-Johnson syndrome, particularly when there is significant skin and mucosal involvement, and a known trigger such as medication or infection. It is crucial to differentiate it from less severe conditions to ensure appropriate management.
Documentation for L51.1 should include a detailed patient history, clinical findings such as the extent of skin and mucosal involvement, any identified triggers, and the patient's response to treatment. Photographic evidence can also be beneficial in supporting the diagnosis.
